Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause - Intensity Therapeutics (NASDAQ:INTS)
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript